Quick Answer
Pyxis Oncology, Inc. reported Operating Income Loss of -$84.42 million for the year ending 2025.
- Pyxis Oncology, Inc. showed an increase of +5.6% in Operating Income Loss from 2024 to 2025.
- This data is from Pyxis Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$3.19 million | Q1 2021: -$35.73 million | Q2 2021: -$5.94 million | Q3 2021: -$11.62 million | Q1 2022: -$31.39 million | Q2 2022: -$25.73 million | Q3 2022: -$28.39 million | Q1 2023: -$20.95 million | Q2 2023: -$18.12 million | Q3 2023: -$25.35 million | Q1 2024: -$5.61 million | Q2 2024: -$20.03 million | Q3 2024: -$23.75 million | Q1 2025: -$22.91 million | Q2 2025: -$19.75 million | Q3 2025: -$23.46 million.
- Over the full 6 years of available data (2020 to 2025), Pyxis Oncology, Inc.'s Operating Income Loss has declined by 554.7%.
- Historical annual values: Fiscal year 2025: -$84.42 million | Fiscal year 2024: -$89.46 million | Fiscal year 2023: -$82.20 million | Fiscal year 2022: -$123.48 million | Fiscal year 2021: -$69.72 million | Fiscal year 2020: -$12.89 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: